Multimodal Assesment of Alzheimer Patients — MultiAD  

Dementia Clinical Trial

Official title: Multimodal Assessment of Cognitive Impairment in Alzheimer Patients

Status Not yet recruiting

Clinical Trial Summary

The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).

The main questions the study aims to answer are:

1. What findings can be used to earlier detect patients that will develop Alzheimers?

2. Which differences are seen between healthy and cognitively impaired patients?

3. Which differences are seen between patients with Alzheimers disease?

Participants will undergo:

• Cognitive tests

• Magnetic resonance imaging (MRI)

• Electroencephalography (EEG)

• Blood sample collection

• Fecal sample collection

• A randomized group will undergo polysomnography analysis.

Clinical Trial Description

The projects aims to map brain changes in patients with mild cognitive impairment (MCI) and Alzheimer's Disease (AD) by combining different assesment modalities.

In the MRI, researchers will get the opportunity to analyse both structural and functional brain changes. In the EEG, changes in elctrical activites will be measured. The blood samples allow researchers to analyse specific dementia and inflammation proteins, while fecal speciments can be used to assess bacterial composition. Additionally, the cognitive testing allow to assess the specific part of cognitive function which is affected. ;

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer Disease, Late Onset
• Cognitive Dysfunction
• Cognitive Impairment
• Dementia
• Mild Cognitive Impairment

• NCT number: NCT06448403
• Study type: Observational [Patient Registry]
• Source: Norwegian University of Science and Technology
• Contact: Axel Sandvig, Prof., MD, PhD
• Phone: 72 57 56 20
• Email: axel.sandvig@ntnu.no
• Status: Not yet recruiting
• Start date: July 1, 2024
• Completion date: December 29, 2030